The undersigned 39 organizations of the AIDS Budget and Appropriations Coalition (ABAC), a workgroup of the Federal AIDS Policy Partnership (FAPP), write to request inclusion of critical language in the final FY2023 Labor, HHS Appropriations bill that is necessary to expand our efforts to end the HIV epidemic in the U.S. As you work to finalize the bill, while ABAC continues to advocate for our coalition’s FY2023 funding requests, we urge you to include language that would modernize the way in which states qualify to be eligible for the HIV set-aside of the Substance Abuse Block Grant (SABG).
Comments on proposed national elimination plan for hepatitis C
HIV+Hep offered comments on the proposed national elimination plan for hepatitis C, asking how the initiative would be funded and authorized, where the initiative would be housed, and why there is a need for the government to purchase medications.
Testimony on Senate FY22 appropriations for HIV and hepatitis programs
As our country continues to respond and recover from the COVID-19 pandemic, which has impacted HIV and hepatitis services, we know we have the science to end two other infectious diseases that have been impacting our country for decades: HIV and hepatitis C. While there still is no cure or vaccine for HIV, we have preventive tools along with treatments that suppress the virus, and together can bring the number of new infections down to a point that we can end HIV.
Letter on FY2022 HIV prevention funding for PrEP in community health centers
We urge Congress to capitalize on the expertise of the community health centers as part of the EHE initiative so that we can expand PrEP and PrEP-related services by increasing funding from the current $102 million to $152 million, as proposed by President Biden’s FY2022 budget.
Support of the PBM Accountability Study Act (HR 1829)
The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.